Antiphospholipid Syndrome (APS) Market Size, Share, Trends, Growth, Key Companies, Emerging Drugs and Epidemiology Forecast

Antiphospholipid Syndrome (APS) Market

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the immune system misguidedly creates antibodies that make one’s blood substantially more likely to clot. It is also known as Hughes syndrome or lupus anticoagulant syndrome. Those with APS make abnormal proteins known as antiphospholipid autoantibodies (aPL) in the blood. This causes blood to flow improperly and can prompt to dangerous clotting in arteries and veins, problems for a developing fetus, and pregnancy miscarriage.

Currently, there is no cure for APS, however, standard initial treatment involves a combination of blood-thinning medications. The most common are heparin and warfarin. Heparin is fast-acting and delivered via injections.


DelveInsight’s “Antiphospholipid Syndrome (APS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Antiphospholipid Syndrome (APS), historical and forecasted epidemiology as well as the Antiphospholipid Syndrome (APS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.



Antiphospholipid Syndrome (APS) Market Key Facts

To estimate the annual incidence and prevalence of and frequency of mortality associated with APS, Duarte-García et al. (2019) conducted a population-based study. For that, an inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on a comprehensive individual medical records review. The investigators estimated the prevalence at 50 per 100,000 population for APS.
According to the American College of Rheumatology, Antiphospholipid antibodies are present in 15–20% of all cases of deep vein thrombosis (blood clots) and one-third of new strokes occurring in people under the age of 50.
According to the American College of Rheumatology (2021), it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men.
According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42–58) per 100,000 population.
According to a study by D’Cruz et. al. (2019), the prevalence in the UK peaked at 50 (95% CI 49 – 55) in females in 2011 and 9.8 (95% CI 8.6 – 11.1) per 100,000 in males in 2012.
According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy was 63% in ages of ≤50 years, 39% ≤40 years, and 18% ≤30 years.
According to an article by the American College of Rheumatology (2021), it was reported that Antiphospholipid antibody syndrome affects women 5 times more commonly than men.


Key Benefits of Antiphospholipid Syndrome (APS) Market Report

Antiphospholipid Syndrome (APS) market report provides an in-depth analysis of Antiphospholipid Syndrome (APS) Market Size, Share, Trend, Epidemiology, and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Antiphospholipid Syndrome (APS) market report will help in developing business strategies by understanding the Antiphospholipid Syndrome (APS) Market trends & developments, key players, and future market competition that will shape and drive the Antiphospholipid Syndrome (APS) market in the upcoming years.
The Antiphospholipid Syndrome (APS) market report covers Antiphospholipid Syndrome (APS) market growth and current treatment practices, emerging drugs, and market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Antiphospholipid Syndrome (APS) patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Get FREE sample copy at:


Antiphospholipid Syndrome (APS) Market

The Antiphospholipid Syndrome (APS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Antiphospholipid Syndrome (APS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of Antiphospholipid Syndrome (APS) market trends and shares an analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Antiphospholipid Syndrome (APS) Epidemiology

The Antiphospholipid Syndrome (APS) epidemiology section covers insights into historical and current Antiphospholipid Syndrome (APS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted Antiphospholipid Syndrome (APS) epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Antiphospholipid Syndrome (APS) Drugs Uptake and Key Market Players

The Antiphospholipid Syndrome (APS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antiphospholipid Syndrome (APS) market or expected to get launched in the market during the study period. The analysis covers Antiphospholipid Syndrome (APS) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Get FREE sample copy at:


Table of Content

Key Insights
Executive Summary 
Antiphospholipid Syndrome (APS) Competitive Intelligence Analysis
Antiphospholipid Syndrome (APS) Market Overview at a Glance
Antiphospholipid Syndrome (APS) Disease Background and Overview
Antiphospholipid Syndrome (APS) Patient Journey
Antiphospholipid Syndrome (APS) Epidemiology and Patient Population
Antiphospholipid Syndrome (APS) Treatment Algorithm, Current Treatment, and Medical Practices
Antiphospholipid Syndrome (APS) Unmet Needs
Key Endpoints of Antiphospholipid Syndrome (APS) Treatment
Antiphospholipid Syndrome (APS) Marketed Products
Antiphospholipid Syndrome (APS) Emerging Therapies
Antiphospholipid Syndrome (APS) Seven Major Market Analysis
Attribute Analysis
Antiphospholipid Syndrome (APS) Market Outlook (7 major markets)
Antiphospholipid Syndrome (APS) Access and Reimbursement Overview
KOL Views on the Antiphospholipid Syndrome (APS) Market.
Antiphospholipid Syndrome (APS) Market Drivers
Antiphospholipid Syndrome (APS) Market Barriers
DelveInsight Capabilities



Other Reports

Eczema Market

DelveInsight’s “Eczema Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Eczema, historical and forecasted epidemiology as well as the Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States